

Title (en)
INNATE IMMUNE SYSTEM MODIFICATION FOR ANTICANCER THERAPY

Title (de)
MODIFIZIERUNG DES ANGEBORENEN IMMUNSYSTEMS FÜR KREBSTHERAPIE

Title (fr)
MODIFICATION DU SYSTEME IMMUNITAIRE INNE POUR UNE THERAPIE ANTICANCEREUSE

Publication
EP 3201322 A4 20180530 (EN)

Application
EP 15847848 A 20150929

Priority
• US 201462059342 P 20141003
• US 2015052898 W 20150929

Abstract (en)
[origin: WO2016054013A1] The present invention relates to the discovery of a role of the nuclear receptor retinoid-related orphan receptor gamma (RORgamma) in tumor suppression. The introduction and expression of RORgamma result in genes activation within innate immune cells that trigger recognition and suppression of tumor cells. Thus, in various embodiments described herein, the invention encompasses a composition or a cell comprising a viral vector comprising nucleic acid sequences encoding RORgamma under the control of a neutrophil specific promoter. Additionally, the invention relates to methods of treating cancer by administering to a subject a composition that confers or increases innate immune cell anti-tumor immunity, methods for providing anti-tumor immunity in a subject, methods of stimulating innate immune response to a cell population or a tissue in a mammal and methods of diagnosing anti-tumor immunity response. Furthermore, the invention encompasses a kit for carrying out the aforementioned methods.

IPC 8 full level
C12N 5/0787 (2010.01); **A61K 48/00** (2006.01); **C12N 5/0789** (2010.01); **A61K 35/15** (2015.01)

CPC (source: EP US)
A61K 39/001102 (2018.08 - EP US); **A61K 39/461** (2023.05 - EP); **A61K 39/464402** (2023.05 - EP); **A61P 35/00** (2018.01 - EP); **A61P 37/04** (2018.01 - EP); **C07K 14/4702** (2013.01 - US); **C12N 5/0642** (2013.01 - EP US); **C12Q 1/6886** (2013.01 - US); **A61K 2039/5156** (2013.01 - US); **A61K 2039/572** (2013.01 - EP US); **A61K 2239/31** (2023.05 - EP); **A61K 2239/38** (2023.05 - EP); **A61K 2239/56** (2023.05 - EP); **C12N 2501/38** (2013.01 - EP US); **C12N 2501/385** (2013.01 - EP US); **C12N 2510/00** (2013.01 - EP US); **C12N 2740/16043** (2013.01 - EP US); **C12Q 2600/158** (2013.01 - US)

Citation (search report)
• [A] RAICHUR S ET AL: "Retinoid-related orphan receptor regulates several genes that control metabolism in skeletal muscle cells: links to modulation of reactive oxygen species production", JOURNAL OF MOLECULAR ENDOCRINOLOGY., vol. 39, no. 1, July 2007 (2007-07-01), pages 29 - 44, XP055467722, ISSN: 0952-5041, DOI: 10.1677/jme.1.00010
• [A] SLOMINSKI A T ET AL: "ROR[alpha] and ROR [gamma] are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D", FASEB J., vol. 28, no. 7, 1 July 2014 (2014-07-01), pages 2775 - 2789, XP055467724, ISSN: 0892-6638, DOI: 10.1096/fj.13-242040
• [A] TAYLOR P R ET AL: "Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, ROR[gamma]t and dectin-2", NATURE IMMUNOLOGY, vol. 15, no. 2, February 2014 (2014-02-01), pages 143 - 151, XP055467725, ISSN: 1529-2908, DOI: 10.1038/ni.2797
• [AP] STRAUSS L ET AL: "RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopenia", CANCER CELL, vol. 28, no. 2, 10 August 2015 (2015-08-10), pages 253 - 269, XP029258671, ISSN: 1535-6108, DOI: 10.1016/J.CCELL.2015.07.006
• See also references of WO 2016054013A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2016054013 A1 20160407; EP 3201322 A1 20170809; EP 3201322 A4 20180530; JP 2017532325 A 20171102;
US 2017218036 A1 20170803

DOCDB simple family (application)
US 2015052898 W 20150929; EP 15847848 A 20150929; JP 2017517701 A 20150929; US 201515515075 A 20150929